

Medications Development Centers (MDC)

The Medications Development Centers (MDC) are a group of seven research center grants awarded around the country focusing on testing new or marketed medications for substance abuse treatment.

Mission:

To support the clinical development of new medications, or new indications for marketed medications for substance abuse treatment or nicotine dependence.

Obtain abstracts of grants and contact information.

Locations:

Cocaine Pharmacotherapy Targeting Dopamine & GABA
Baylor College of Medicine
Dept. of Psychiatry & Behavioral Sciences
1 Baylor Plaza
Houston, TX 77030-3498
Thomas R. Kosten, M.D.
kosten@bcm.edu

Center for Research Improving Treatment of Drug Abuse

University of Pennsylvania School of Medicine

Dept. of Psychiatry

Treatment Research Center

3900 Chestnut Street

Philadelphia, PA 19104

Charles P. O'Brien, M.D.

obrien@mail.trc.upenn.edu

Innovative Approaches for Cocaine Pharmacotherapy

University of Pennsylvania School of Medicine

Dept. of Psychiatry

Treatment Research Center

3900 Chestnut Street

Philadelphia, PA 19104

Helen M. Pettinati, Ph.D.

pettinati_h@mail.trc.upenn.edu

Methamphetamine Pharmacotherapy Development Center

California Pacific Medical Center Research Institute

San Francisco, CA 94107

John Mendelson, M.D.

mendelje@cpmcri.org

Novel Medications Approaches for Substance Abuse

New York State Psychiatric Institute
1051 Riverside Drive
New York, NY 10032
Herbert D. Kleber, M.D.
hdk3@columbia.edu

Substance Abuse Research & Medications Development Center
University of Texas Health Sciences Center
Box 20036
Houston, TX 77225
F. Gerard Moeller, M.D.
frederick.g.moeller@uth.tmc.edu

UCLA Medication Development Unit for Stimulant Abuse
University of California, Los Angeles
David Geffen School of Medicine
Dept. of Family Medicine
10880 Wilshire Boulevard, Suite 1800
Los Angeles, CA 90095-9087
Steven Shoptaw, Ph.D.
sshoptaw@mednet.ucla.edu